Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults
NCT ID: NCT01430702
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2011-09-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions
NCT01600677
Electronic Medication Adherence Reporting and Feedback During Care Transitions
NCT03475030
Adherence to Polypharmacy in Patients With Opioid Substitution Therapy Using Electronics
NCT02701660
An Enhanced Medication Monitoring Program
NCT01105104
Effect of Medication Management at Home Via Pharmacy Home Televisits
NCT04340570
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Programs to improve the medication reconciliation process have largely been effective, but have limitations including the expense associated with recruiting, training, and retaining care transition healthcare professionals (e.g., nurses and nurse practitioners), the ability to provide services within a finite geographic area, and the retrospective nature of the reconciliation process, which usually occurs in the home following hospital discharge. The investigators short-term objective is to use Pennsylvania Department of Aging resources to assess the feasibility of using a telemedicine medication delivery unit for frail older adults that require medication assistance in their home immediately following an acute hospitalization. As part of this feasibility assessment, the investigators will assess several methods and intervention-related components.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Computerized medication delivery unit
Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)
The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)
The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted during the study period for a nonpsychiatric condition to UPMC Presbyterian Hospital.
* Documented in their medical record at least 1 of 11 diagnoses, including: stroke, congestive heart failure, coronary artery disease, cardiac arrhythmias, chronic obstructive pulmonary disease, diabetes mellitus, spinal stenosis, hip fracture, peripheral vascular disease, deep venous thrombosis, and pulmonary embolism.
* Prescribed \> 5 and \< 20 regularly scheduled (i.e., non-PRN) prescription medications.
* Be from and return to a home setting (not assisted living, skilled nursing, program for all-inclusive care of the elderly, etc).
* Reside within a predefined geographic radius (i.e., Allegheny, Beaver, Butler, Fayette, Washington or Westmoreland Counties) of the hospital.
* Have a working telephone.
* Be English speaking.
* Have an informal caregiver or support person.
Exclusion Criteria
* Enrolled in or plan to enroll into hospice.
* Plans to travel in the next 30 days.
* Participating in another research protocol.
* Have evidence in the chart of a diagnosis of active delirium.
* Have evidence in the chart of a diagnosis of dementia.
* Have evidence in the chart of legal blindness.
* Unable to demonstrate appropriate use of the EMMA medication delivery unit.
* Unable to receive ATT wireless services data plan based on physical address.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pittsburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven M. Handler, MD, PhD, CMD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh -- of the Commonwealth System of Higher Education
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FY2010-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.